Biopharma Needs a Flexible Talent Model Now

Biopharma Firms Need a Flexible Talent Model to Survive the Hire Cut Rehire Cycle

Biopharma has a habit. It cuts hard, then rehires fast. It rarely plans for the gap in between. That habit is costly, and 2026 is exposing it again, right as pipelines mature and competition for the same specialist talent intensifies.

The cycle repeats, and the numbers show it

Fierce Biotech’s layoff tracker recorded roughly 43,242 biopharma job cuts across 2025. Patent cliffs, pricing pressure and post-pandemic realignment drove most of the cuts. Even so, the picture is already shifting. By the second quarter of 2026, only 17 companies reported layoffs, down from 33 in the first quarter. PharmaVoice summed up the shift well. In its words, 2025 was the surge, and 2026 is the industry’s chance to turn the page.

That turn is the hard part. Most restructuring plans focus on the cut itself. Far fewer plan for what happens once pipelines mature and hiring restarts. So the same functions trimmed twelve months ago are often the ones under pressure to scale again now.

Fixed headcount cannot flex at this cycle’s speed

Here is the core problem. A permanent-only workforce model adds or removes people slowly. Restructuring cycles do not move slowly at all. A round of cuts can land in weeks. The recovery, once pipelines mature, often demands specialist hires just as fast.

This mismatch creates real cost. Rehiring after a reduction means rebuilding sourcing relationships from scratch. Often, it means paying more for people the firm let go a year earlier. Worse, those people are now working for a competitor. And every other biopharma firm recovering from its own cuts is chasing the same talent at the same time.

There is a reputational cost too. Candidates remember which employers cut without a clear plan. They also remember which employers explained the change well. That memory shapes how easily a firm can rehire from the same pool a year later.

Specialist functions feel this hardest

R&D and manufacturing functions usually take the deepest cuts in a downturn. They are also the hardest to rebuild once the pipeline turns. Specialist scientists and process engineers take years to reach full skill, not months. So losing that experience in a restructure, costs far more than the headcount number alone suggests.

Office policy and site changes add a further layer of risk on top of formal cuts. Even with no redundancy at all, a policy shift can push good staff toward the door. This often happens right when the firm needs their skills back most. Many biopharma firms are learning this the hard way in 2026. Commercial confidence is returning faster than in-house teams can rebuild.

A blended talent model absorbs the swing

This is exactly the gap a total talent solution closes. Instead of one fixed headcount number to cut and rebuild, a blended model splits the workforce differently. There is a stable core. Alongside it sits a flexible layer of contract, interim and project talent. That flexible layer absorbs most of the swing. The core stays largely intact.

In practice, this means a restructure does not have to sever every specialist relationship. Some contract roles wind down naturally as programmes close. This carries less reputational cost than a hard redundancy round. When demand returns, that same flexible layer can scale back up fast. It draws on people who already know the organisation, not a cold search.

An MSP model adds a second layer of protection. It gives one team oversight of every contingent worker across the business. That beats five agencies managing separate pools with no shared view. As a result, redeploying people internally becomes far easier. Nobody releases someone from one team, only to open the same role in another team three months later.

An RPO relationship, run alongside this, keeps market maps warm through a quiet period. So when hiring restarts, the search does not begin from zero. Instead, it begins from a relationship maintained during this phase, not abandoned during it.

Speed to rebuild

None of this removes the need for hard decisions in a genuine downturn. Some restructuring is unavoidable, and no talent model changes that. Still, a blended model changes the shape of the swing on either side of that decision. It also changes how fast the organisation rebuilds capability once conditions improve. That difference compounds over several cycles, not just the current one, because a firm known for handling change well finds it easier to attract talent back each time.

For talent leaders and procurement teams reviewing 2026 plans, the real question is not whether this cycle repeats. Biopharma’s recent history suggests it will. Instead, the question is this: will the next swing be absorbed by a flexible model, or will it mean another costly round of cutting and rebuilding from scratch?

By Dave Watson, VP Talent Solutions, Skills Alliance Enterprise